Russell G. Jones, Edward J. Pearce  Immunity 

Slides:



Advertisements
Similar presentations
M1 – Immunology EFFECTOR T CELL FUNCTIONS (Part I) March 27, 2009 Ronald B. Smeltz, Ph.D. Microbiology and Immunology
Advertisements

AMPK—Sensing Energy while Talking to Other Signaling Pathways
MYC, Metabolism and Cancer
Rigel J. Kishton, Madhusudhanan Sukumar, Nicholas P. Restifo 
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
Miriam Marqués, Francisco X. Real  European Urology 
IRS-1: Auditing the effectiveness of mTOR inhibitors
Differentiation and Functions of CD8+ Effector T Cells
Cell to Cell Communication via Enzyme Linked Receptors
Sphingolipid Signaling in Metabolic Disorders
Nutrient-Sensing Mechanisms across Evolution
The Role of CNS Fuel Sensing in Energy and Glucose Regulation
Taking T Cell Priming Down a Notch: Signaling through Notch Receptors Enhances T Cell Sensitivity to Antigen  Timothy J. Thauland, Manish J. Butte  Immunity 
A Flt3L Encounter: mTOR Signaling in Dendritic Cells
mTORC1: Turning Off Is Just as Important as Turning On
Figure 1 mTOR complex biology
The pathway signalling starts with the binding of insulin or growth factors to insulin receptors. The pathway signalling starts with the binding of insulin.
Maria M. Mihaylova, David M. Sabatini, Ömer H. Yilmaz  Cell Stem Cell 
Kaitlin A. Read, Michael D. Powell, Paul W. McDonald, Kenneth J
Metabolic control of regulatory T cell development and function
Identification of TOR Signaling Complexes
Is REDD1 a Metabolic Éminence Grise?
Metabolic Reprogramming of Immune Cells in Cancer Progression
Foxo1 and Foxo3 help Foxp3 Immunity
IL-2: Change Structure … Change Function
Complementing T Cells’ Functions: Bringing in Metabolism Matters
Rapamycin: One Drug, Many Effects
Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills  Cancer Cell 
The PI3K Pathway in Human Disease
Metabolic Regulation of the Immune Humoral Response
Dietmar M.W. Zaiss, William C. Gause, Lisa C. Osborne, David Artis 
FGFR Signaling as a Target for Lung Cancer Therapy
IRS-1: Auditing the effectiveness of mTOR inhibitors
BTLA+ Dendritic Cells: The Regulatory T Cell Force Awakens
An Emerging Role of mTOR in Lipid Biosynthesis
AMPK—Sensing Energy while Talking to Other Signaling Pathways
Humoral and Cell Mediated Immunity
mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells
Metabolic Instruction of Immunity
Mitochondria in the Regulation of Innate and Adaptive Immunity
Long Noncoding RNA in Hematopoiesis and Immunity
Biosensors and their applications in microbial metabolic engineering
AKT/PKB Signaling: Navigating the Network
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Plasma Cells for Hire: Prior Experience Required
Role of the Microbiota in Immunity and Inflammation
Figure 1 The mTOR signalling pathway
Bryan Krock, Nicolas Skuli, M. Celeste Simon  Cell Metabolism 
AKT/PKB Signaling: Navigating Downstream
From Vanilla to 28 Flavors: Multiple Varieties of T Regulatory Cells
Brassinosteroids Regulate Root Growth, Development, and Symbiosis
Rapamycin: One Drug, Many Effects
John D. Gordan, Craig B. Thompson, M. Celeste Simon  Cancer Cell 
Jonathan D. Powell, Greg M. Delgoffe  Immunity 
mTOR and Akt Signaling in Cancer: SGK Cycles In
The Immune System as a Sensor of the Metabolic State
Brian K. Kennedy, Dudley W. Lamming  Cell Metabolism 
Caloric Restriction in mTORC1 Control of Intestinal Homeostasis
Tobias B. Huber, Gerd Walz, E Wolfgang Kuehn  Kidney International 
Anthony T. Phan, Ananda W. Goldrath, Christopher K. Glass  Immunity 
Volume 35, Issue 6, Pages (December 2011)
Dendritic-Cell-Based Therapeutic Cancer Vaccines
VHL Brings Warburg into the Memory Spotlight
Lysosomal Rag-ulation of mTOR Complex 1 Activity
At 17, In-10's Passion Need Not Inflame
Follicular Helper T Cells: Lineage and Location
Dietmar M.W. Zaiss, William C. Gause, Lisa C. Osborne, David Artis 
Successful targeting of ErbB2 receptors—is PTEN the key?
Marking Emerging β- and γδ-Selected T Cells
T Helper Cell Differentiation: Understanding the Needs of Hierarchy
Presentation transcript:

MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue- Resident Immune Cells  Russell G. Jones, Edward J. Pearce  Immunity  Volume 46, Issue 5, Pages 730-742 (May 2017) DOI: 10.1016/j.immuni.2017.04.028 Copyright © 2017 Terms and Conditions

Figure 1 mTORC1 and mTORC2 Mediate Separate but Overlapping Cellular Functions In resting cells, or when extracellular amino acid concentrations are low, mTORC1 is dissociated from lysosomes and is inactive (left side of lysosome). When immune cells become activated, they express amino acid transporters to allow them to more efficiently acquire extracellular amino acids. This is coordinated with Akt-dependent signals that alleviate TSC2-dependent inhibition of Rheb, to allow recruitment of mTORC1 to lysosomes, where it becomes activated by Rheb (right side of lysosome). Active mTORC1 phosphorylates S6K and 4EBP, with the net result of increasing ribosomal biogenesis and the translation of mRNA subsets coding for a variety of proteins, but especially proteins involved in anabolic metabolic pathways and immune mediators. This enables activated cells to generate more metabolic intermediates for biosynthesis to support cell growth, proliferation, and effector functions. mTORC2, which can be directly activated by PI3K, also promotes metabolic reprogramming through Akt-mediated activation of hexokinase 2 (HK2) or inhibition of Foxo1. Downstream targets of mTORC2 such as SGK also play direct roles in Th cell differentiation and in cytoskeletal dynamics important for cell movement. Immunity 2017 46, 730-742DOI: (10.1016/j.immuni.2017.04.028) Copyright © 2017 Terms and Conditions

Figure 2 Asymmetric Lymphocyte Division Marked by Differential mTORC1 Segregation Can Dictate Cell Fate During the first cellular division of a naive CD8+ T cell (green), emerging daughter cells assume distinct properties, marked initially by the segregation of mTORC1 into the daughter cell proximal to the antigen-presenting cell. Amino acid transporters (Slc7a5, Slc1a5) are also enriched in proximal cells (red), promoting increased mTORC1 activation and mTORC1-dependent c-Myc expression. Distal daughter cells (yellow) display less mTORC1 activity and increased AMPK activity. This imbalance of key metabolic regulators in the emerging cells leads to metabolic differences in proximal and distal daughter cells such that the former is more glycolytic and anabolic, whereas the latter is more catabolic. Divergent metabolic profiles, enforced by asymmetric mTORC1 distribution, have far-reaching consequences for daughter cell fate, with proximal cells destined to assume effector functions (short-lived Teff cells) and distal cells more likely to persist as long-lived memory cells. Surface markers and intracellular signaling molecules associated with each state are highlighted. Immunity 2017 46, 730-742DOI: (10.1016/j.immuni.2017.04.028) Copyright © 2017 Terms and Conditions

Figure 3 Amino Acid Sensing Is a Critical Control Point for Determining mTORC1 Activation, Metabolic Reprogramming, and Cellular Fate Amino acid sufficiency, particularly branched chain amino acids (BCAAs) and arginine, is sensed by immune cells through a process coupled to mTORC1 activation. When mTORC1 is active, cellular metabolism is anabolic, and catabolic pathways are inhibited. This allows cellular growth, proliferation, and the development of effector functions to proceed. Amino acid limitation, due to low supply in the microenvironment or consumption by other immune cell types (M2 alternatively activated macrophages, MDSCs, or Treg cells), reduces mTORC1 activation and prevents metabolic reprogramming to support cellular activation. Expression by regulatory immune cells of enzymes that break down amino acids is a primary immune system intrinsic mechanism through which effector immune cell activation is regulated. Other events, such as infection or cancer, that lead to changes in amino acid availability, can effectively limit immune cell activation through the same pathway. Immunity 2017 46, 730-742DOI: (10.1016/j.immuni.2017.04.028) Copyright © 2017 Terms and Conditions